SCM
IMMU

Scopia Capital Management’s Immunomedics Inc IMMU Stock Holding History

Scopia Capital Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,937,843
Closed -$37.2M – 30
2019
Q1 		$37.2M Buy
+1,937,843
New +$31.2M 1.38% 18

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Scopia Capital Management's IMMU Position: Q2 2019 in Review

Scopia Capital Management sold out of Immunomedics Inc (IMMU) in Q2 2019, closing a stake of 1,937,843 shares — an estimated $37.2M sold.

Scopia Capital Management first reported a position in IMMU in Q1 2019 and held it in 1 quarter. The position peaked at $37.2M in Q1 2019. 204 funds tracked by Wall St. Rank hold IMMU as of Q2 2019.

  • Scopia Capital Management reported no remaining Immunomedics Inc position as of Q2 2019 after selling out during the quarter.
  • Scopia Capital Management sold 1,937,843 Immunomedics Inc shares in Q2 2019, an estimated $37.2M.
  • Scopia Capital Management first reported a position in Immunomedics Inc in Q1 2019 and held it in 1 quarter.
  • Scopia Capital Management's Immunomedics Inc position peaked at $37.2M in Q1 2019.
  • 204 funds tracked by Wall St. Rank held Immunomedics Inc as of Q2 2019.

Based on Scopia Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.